Ideaya Biosciences (IDYA) said Monday it has successfully completed a Type D meeting with the US Food and Drug Administration on the design of a phase 3 registrational trial to evaluate the safety and efficacy of its darovasertib precision oncology candidate to treat primary uveal melanoma.
The trial is expected to start in H1 and will use eye preservation and the proportion of patients with vision loss as its primary endpoints and with no detriment to event-free-survival as a secondary endpoint for both cohorts, the oncology company said.
Other secondary endpoints will include overall response rate, the proportion of patients with clinically significant macular edema and the proportion of subjects with legal blindness.
Shares were almost 6% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。